We are developing potential medicines that improve the healthspan of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.
Cardiovascular diseases are the leading cause of death in the U.S. and in many places around the world. We’re focused on finding potential treatments for people with heart failure and hypertrophic cardiomyopathy.
Neuromuscular diseases can cause loss of muscle function, muscle weakness and fatigue. Our goal is develop potential therapies for people with amyotrophic lateral sclerosis and spinal muscular atrophy.
- Cytokinetics Reports First Quarter 2019 Financial Results
- Cytokinetics to Hold Annual Meeting of Stockholders
- Cytokinetics Announces Results of FORTITUDE-ALS, a Phase 2 Clinical Trial of Reldesemtiv in Patients With ALS, Presented at American Academy of Neurology Annual Meeting